On July 23-24, 2026, at FDA’s White Oak Campus in Silver Spring, Maryland, the Pharmacy Compounding Advisory Committee (PCAC) will decide the future of seven peptides that millions of Americans use. If these peptides are recommended for the 503A Bulk Drug Substances List, licensed compounding pharmacies could legally produce them with a prescription. Here’s the full breakdown.
| Peptide | Nominated Use | Why Women Care |
|---|---|---|
| BPC-157 | Ulcerative colitis | Gut healing, tissue repair, interstitial cystitis (pilot study: 10/12 women symptom resolution) |
| KPV | Wound healing, inflammatory conditions | Autoimmune conditions (80% of patients female), IBD, gut inflammation |
| TB-500 | Wound healing | Post-surgical recovery, C-section healing, tissue repair |
| MOTS-C | Obesity, osteoporosis | PCOS insulin resistance, menopause-related bone loss, metabolic support |
| Peptide | Nominated Use | Why Women Care |
|---|---|---|
| DSIP / Emideltide | Opioid withdrawal, chronic insomnia, narcolepsy | Perimenopausal insomnia, sleep architecture restoration |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Cognitive enhancement, BDNF support, brain fog in perimenopause |
| Epitalon | Insomnia | Telomere support, pineal gland function, longevity |
The PCAC is an advisory committee. Its recommendations are non-binding — the FDA is not obligated to follow them. Even a positive recommendation doesn’t immediately change anything. The formal process is: PCAC reviews evidence and votes on a recommendation, FDA considers the recommendation, if positive, FDA initiates rulemaking to add the substance to the 503A list, and rulemaking requires public comment and finalization.
Legal experts have described the July meeting as a necessary procedural step rather than the finish line. Without PCAC review, any modification to the 503A list would likely face legal challenge.
The FDA is specifically reviewing BPC-157 for ulcerative colitis — not for general tissue repair, not for interstitial cystitis, not for gut healing broadly. If approved for 503A compounding, it would likely be compoundable only for the nominated indication. However, once a substance is on the 503A list, providers have broader latitude in how they prescribe compounded medications.
KPV’s nomination for wound healing and inflammatory conditions is particularly relevant for women with autoimmune diseases. KPV activates melanocortin receptors to suppress NF-κB, the master inflammatory switch, while promoting anti-inflammatory IL-10 production. Research shows effectiveness across multiple autoimmune conditions including Crohn’s disease, ulcerative colitis, and psoriasis.
The osteoporosis nomination is critical for postmenopausal women. MOTS-C is a mitochondrial-derived peptide that regulates metabolic homeostasis and has shown effects on insulin sensitivity and bone metabolism. If approved for compounding, it would be the first peptide specifically available for osteoporosis through the compounding pathway.
The PCAC meeting will be held at FDA White Oak Campus with a virtual attendance option. Background materials will be published at least two business days before the meeting. Public comment submissions were accepted through July 9, 2026. Nominators of each substance have been invited to make brief supporting presentations.
FemPeptides will publish a live analysis after each day’s proceedings. Follow the blog for updates.
If you’re currently using any of these peptides through a research vendor, the July meeting doesn’t immediately change your situation. These peptides remain in a regulatory gray zone: not explicitly banned, not approved, but headed toward formal review. Some compounding pharmacies may become more cautious in the months surrounding the meeting. If you’re currently receiving any of these peptides through a compounding pharmacy with a prescription, stay in contact with your pharmacy and prescribing physician about any changes.
Not immediately. The PCAC makes a non-binding recommendation to the FDA. If positive, the FDA must then initiate formal rulemaking (including public comment) to add BPC-157 to the 503A list. This process takes months to over a year. The July meeting is a necessary step, not the final one.
Yes. The meeting at FDA White Oak Campus in Silver Spring, MD is open to the public with a virtual attendance option. Background materials will be published at least two business days before the meeting. Contact PCAC@fda.hhs.gov or call 240-402-2507 for details.
A negative recommendation doesn't permanently bar a peptide from compounding, but it makes the path much harder. The FDA would be unlikely to add a substance to the 503A list against its own advisory committee's recommendation. The nominator could resubmit with additional evidence in the future.
Yes. A second PCAC meeting is planned before the end of February 2027 to review five additional peptides: GHK-Cu (injectable), Melanotan II, Cathelicidin LL-37, Dihexa acetate, and PEG-MGF. Non-injectable GHK-Cu is following a separate evaluation path.